Zynerba Pharmaceuticals (NASDAQ:ZYNE) – Stock analysts at Seaport Global Securities issued their Q1 2018 earnings per share estimates for shares of Zynerba Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 13th, according to Zacks Investment Research. Seaport Global Securities analyst V. Bernardino forecasts that the company will post earnings per share of ($0.65) for the quarter. Seaport Global Securities currently has a “Buy” rating on the stock.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its quarterly earnings data on Monday, March 12th. The company reported ($0.60) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.60). During the same quarter in the prior year, the firm posted ($0.71) EPS.
ZYNE has been the topic of a number of other research reports. HC Wainwright set a $23.00 price objective on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 6th. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, December 8th. Cantor Fitzgerald began coverage on shares of Zynerba Pharmaceuticals in a research note on Monday, March 5th. They set a “buy” rating and a $17.00 target price for the company. ValuEngine lowered shares of Zynerba Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, April 2nd. Finally, Ladenburg Thalmann Financial Services began coverage on shares of Zynerba Pharmaceuticals in a research note on Monday, January 29th. They set a “buy” rating and a $25.50 target price for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.86.
ZYNE stock traded down $0.31 during mid-day trading on Thursday, reaching $8.82. 152,829 shares of the stock traded hands, compared to its average volume of 315,577. Zynerba Pharmaceuticals has a one year low of $5.42 and a one year high of $25.95. The stock has a market capitalization of $123.82, a price-to-earnings ratio of -3.56 and a beta of 4.94.
In other Zynerba Pharmaceuticals news, major shareholder Michael Rapp acquired 10,000 shares of the stock in a transaction that occurred on Thursday, March 22nd. The stock was bought at an average cost of $9.28 per share, with a total value of $92,800.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 9.91% of the stock is owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors purchased a new stake in Zynerba Pharmaceuticals in the second quarter worth about $110,000. Zeke Capital Advisors LLC purchased a new stake in Zynerba Pharmaceuticals in the third quarter worth about $114,000. The Manufacturers Life Insurance Company purchased a new stake in Zynerba Pharmaceuticals in the second quarter worth about $158,000. Cowen Inc. purchased a new stake in Zynerba Pharmaceuticals in the third quarter worth about $167,000. Finally, New York State Common Retirement Fund purchased a new stake in Zynerba Pharmaceuticals in the second quarter worth about $207,000. 28.92% of the stock is owned by institutional investors.
WARNING: “Zynerba Pharmaceuticals (ZYNE) Forecasted to Earn Q1 2018 Earnings of ($0.65) Per Share” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/analysts-offer-predictions-for-zynerba-pharmaceuticals-incs-q1-2018-earnings-zyne.html.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.